Editorial Comment from Dr Teishima and Dr Matsubara to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first ‐line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
International Journal of Urology, EarlyView.
Source: International Journal of Urology - Category: Urology & Nephrology Authors: Jun Teishima M.D., Ph.D.
,
Akio Matsubara M.D., Ph.D. Source Type: research
More News: Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology